Niagen Bioscience is trading 5.8% down at $2.35 on October 30, 2026; the specific catalyst remains unclear.
- No new company announcement was found clearly tied to the decline.
- The latest major company news was an October 22 launch of its at-home injection kit; third-quarter results are scheduled for November 4.
- Broader markets faced pressure amid technology earnings concerns, while healthcare was reported to be gaining. Available evidence does not establish a market-wide or sector-specific explanation.